SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Infinity Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?


To: Mike McFarland who wrote (166)4/15/2008 5:17:34 PM
From: Mike McFarland  Read Replies (1) | Respond to of 210
 
Preclinical Data Highlighting Potential of Retaspimycin in
Treating Non-Small Cell Lung Cancer With Acquired Drug
Resistance Presented by Infinity and MedImmune At AACR

Preclinical Data Also Support Evaluation of Retaspimycin in
HER2-Positive Breast Cancer and Metastatic Melanoma

investor.ipi.com